drugset / Trial / NCT00224445

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445

Phase 4 Completed 100 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of a simple, once-daily antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada combined with atazanavir boosted with ritonavir in treatment naive patients.

Timeline

Start
2005-09
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 300 mg Oral
Subject Tenofovir Small molecule 200 mg Oral
Subject Tenofovir Small molecule 300 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral